Health
New Covid-19 vaccine demonstrates ’89 efficacy’ with UK having 60m orders – Bridport and Lyme Regis News
A trial was carried out in conjunction with the UK Government’s Vaccine Taskforce.
An experimental Covid-19 vaccine appears to offer strong protection in late-stage UK and South Africa studies, said manufacturer Novavax.The UK has secured access to 60 million doses of the vaccine, called NVX-CoV2373.The protein-based vaccine candidate was shown to be 89.3% effective at preventing coronavirus in participants in its Phase 3 clinical trial in the UK, which enrolled more than 15,000 people between 18-84, of which 27% were older than 65, Novavax said.
“NVX-CoV2373 is the first vaccine…
-
Noosa News18 hours agoQueensland weather forecast sees sunny weather for last week of winter
-
General21 hours agoFirst home buyers score early access to deposit scheme
-
Noosa News19 hours agoForum responds to urgent homelessness issues in Nambour
-
Business16 hours agoWhy the Betashares Nasdaq 100 ETF could be a perfect buy and hold pick